GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance. 1w. GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American ... driven by strong performance across all ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma therapy approval.

Analysts are also bullish on the stock because of the notable performance of its specialty medicine segment, which is GSK plc’s (NYSE:GSK) largest business area.

GSK will be responsible for making ‘success-based’ milestone payments and tiered royalties to Novartis. GSK Stock’s Performance Year to date, shares of GSK have gained 7% against the ...

Also Read: GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion If approved, tebipenem HBr would be the first oral carbapenem antibiotic for patients in the U.S. who suffer from cUTIs.

GSK’s Price Performance, Valuation & Estimate Movement. GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.